Regulatory status last checked: October 14, 2026
NMN is not currently excluded from the definition of a dietary supplement under the FDA's drug-preclusion provision. In September 2025, FDA reversed its earlier position and stated that NMN had been marketed as a dietary supplement in the United States before it was authorized for investigation as a new drug.

That does not mean NMN is “FDA-approved.” Dietary supplements are not approved by FDA for safety and effectiveness before marketing in the way drugs are.
The clearest way to describe the current U.S. situation is:
- FDA said in 2022 that NMN was excluded from the dietary-supplement definition under the drug-preclusion clause.
- FDA reconsidered that position in 2025.
- FDA now says NMN is not excluded under that clause.
- FDA's current New Dietary Ingredient database includes a 2025 β-NMN notification with a response dated January 28, 2026.
- None of this means every NMN product is FDA-approved, automatically lawful, safe, effective, or equivalent.
NMN FDA Status at a Glance
| Question | Current answer |
|---|---|
| Is NMN banned in the U.S.? | FDA no longer considers NMN excluded from the dietary-supplement definition under the drug-preclusion clause. |
| Is NMN legal in the U.S.? | NMN is no longer excluded on the basis FDA relied on in 2022. Specific products still must comply with all applicable supplement laws and requirements. |
| Is NMN FDA-approved? | No. FDA does not preapprove dietary supplements for safety and effectiveness. |
| Did FDA ban NMN in 2022? | FDA determined in 2022 that NMN was excluded from the dietary-supplement definition because of the drug-preclusion provision. |
| Did FDA reverse that decision? | Yes. In September 2025, FDA said it no longer finds NMN excluded under section 201(ff)(3)(B). |
| What is NDI 1444? | A New Dietary Ingredient notification for β-NMN/NMN submitted by Effepharm in November 2025, with an FDA response dated January 28, 2026. |
| Does NDI 1444 mean FDA approved NMN? | No. An NDI notification is a regulatory filing process, not product approval or proof of efficacy. |
| Is NMN approved for anti-aging? | No. NMN is not FDA-approved to treat aging, extend lifespan, or prevent disease. |
Why Did FDA Say NMN Could Not Be Sold as a Dietary Supplement?
The controversy centered on a provision of the Federal Food, Drug, and Cosmetic Act commonly called the drug-preclusion or race-to-market clause.

In simplified terms, the dietary-supplement definition generally excludes an ingredient that:
- was authorized for investigation as a new drug;
- became the subject of substantial clinical investigations that were made public;
- and had not already been marketed as a dietary supplement or food before the relevant drug-investigation point.
In 2022, FDA concluded that NMN fell on the drug side of that line.
What Happened in 2022?
FDA's position changed during its review of New Dietary Ingredient notifications involving β-NMN.
In October and November 2022, the agency communicated that NMN was excluded from the dietary-supplement definition under section 201(ff)(3)(B)(ii) because it had been authorized for investigation as a new drug before what FDA then considered qualifying prior supplement or food marketing.1
The November 2022 supplemental response to NDI 1259 stated that NMN could not be marketed as or in a dietary supplement under that interpretation.
This is the origin of the shorthand:
“FDA banned NMN.”
That shorthand is imprecise.
FDA did not issue a general consumer-product recall declaring NMN toxic. The agency made a legal classification decision about whether NMN fit the statutory definition of a dietary supplement.
Was the 2022 FDA Decision About NMN Safety?
No. The central 2022 dispute was regulatory classification, not a finding that NMN had been proven toxic.
FDA's drug-preclusion analysis asks whether an ingredient qualifies for the dietary-supplement category under federal law.
That question is separate from:
- whether NMN raises NAD+;
- whether a particular amount is safe;
- whether NMN has clinical benefits;
- whether a finished supplement is high quality.
A legal-status decision should not be presented as proof of either safety or danger.
For human safety evidence, see our NMN side effects and safety guide.
Why Did FDA Reverse Its Position in 2025?
After FDA's 2022 decision, industry groups challenged the agency's interpretation.
The Natural Products Association and Alliance for Natural Health USA filed a citizen petition asking FDA to reconsider NMN's status.
On September 29, 2025, FDA issued its response.2
The agency stated:
FDA no longer finds that NMN is excluded from the dietary-supplement definition under section 201(ff)(3)(B).
The agency concluded that NMN had been marketed as a dietary supplement in the United States before NMN was authorized for investigation as a new drug.
That chronology changed the outcome of the drug-preclusion analysis.
What Did FDA Change About Its Interpretation?
The dispute involved not only dates but also how FDA interpreted prior marketing.
The 2025 petition response explains that FDA reconsidered whether previous marketing had to be shown to be lawful before it could count as prior marketing under the race-to-market provision.
FDA ultimately concluded that the statute did not require the prior marketing to satisfy the extra “lawful marketing” condition the agency had previously applied.
That meant the evidence of NMN being marketed in the United States before the drug-investigation authorization could be considered in the analysis.
Is NMN Banned in the USA Today?
Not under the drug-preclusion interpretation FDA relied on in 2022.
FDA's current position is that NMN is not excluded from the definition of a dietary supplement under section 201(ff)(3)(B).
That does not mean every product labeled “NMN” is automatically lawful.
A finished supplement may still face regulatory problems if it is:
- adulterated;
- misbranded;
- contaminated;
- incorrectly labeled;
- marketed with unlawful disease-treatment claims;
- noncompliant with applicable New Dietary Ingredient requirements.
Ingredient-category status and product compliance are not the same thing.
Is NMN Legal in the USA?
FDA no longer considers NMN excluded from the dietary-supplement category under the specific drug-preclusion provision that drove the 2022 controversy.

So the older statement:
“NMN is illegal as a dietary supplement in the U.S.”
is outdated as a description of FDA's current position.
However, “legal” still needs context because dietary-supplement compliance is product-specific.
A company remains responsible for ensuring that its product:
- uses ingredients that can lawfully be marketed;
- meets applicable safety requirements;
- is manufactured appropriately;
- is accurately labeled;
- does not make unlawful drug claims.
Is NMN FDA-Approved?
No.
This is one of the most important distinctions in the entire NMN regulatory discussion.
FDA does not approve dietary supplements for safety and effectiveness before they are marketed.3
Therefore, statements such as:
- “FDA-approved NMN supplement”;
- “FDA approved NMN for anti-aging”;
- “FDA-approved NMN dose”;
are misleading unless they refer to some entirely different FDA-regulated status and explain it precisely.
FDA-Regulated Is Not the Same as FDA-Approved
Dietary supplements are regulated by FDA.
FDA can:
- inspect manufacturing facilities;
- review New Dietary Ingredient notifications;
- monitor labeling and marketing;
- investigate complaints;
- review adverse-event reports;
- take enforcement action against adulterated or misbranded products.
That regulatory oversight is different from premarket drug approval.
What Is an NDI Notification?
NDI stands for New Dietary Ingredient.
Under federal law, manufacturers or distributors of supplements containing certain new dietary ingredients must submit information to FDA at least 75 days before marketing the ingredient under the proposed conditions of use.
The notification is intended to provide the basis for the notifier's conclusion that the ingredient is reasonably expected to be safe under those conditions.
An NDI notification is not a drug approval application.
What Is NMN NDI 1444?
FDA's current public New Dietary Ingredient notification list includes:
- Notification: 1444
- Ingredient: beta-nicotinamide mononucleotide (β-NMN) or NMN
- Firm: Effepharm, Ltd.
- Submission date: November 17, 2025
- FDA response date: January 28, 2026.4
This record is important because it demonstrates that NMN is again moving through FDA's New Dietary Ingredient framework following the 2025 change in regulatory interpretation.
Does NDI 1444 Mean NMN Is FDA-Approved?
No.
An NDI notification and FDA response are not equivalent to:
- approval of NMN as a drug;
- approval of NMN for anti-aging;
- approval of every NMN ingredient source;
- approval of every finished NMN supplement;
- proof that every NMN amount is safe;
- proof of clinical effectiveness.
The notification concerns a particular ingredient, notifier, manufacturing context, conditions of use, and safety submission.
It should not be turned into a blanket “FDA-approved NMN” marketing claim.
What Happened to the Older NMN NDI Letters?
Before the 2022 exclusion controversy, several companies had submitted NMN New Dietary Ingredient notifications.
After FDA changed its position in 2022, the agency sent supplemental responses addressing NMN's exclusion from the dietary-supplement definition.
Following the September 2025 petition response, FDA subsequently set aside earlier exclusion determinations in communications to NMN ingredient notifiers.
This is another reason older articles describing the 2022 regulatory position as permanent are now outdated.
Why Did Amazon Stop Selling NMN?
Amazon's marketplace decision is related historically to the FDA controversy but is not the same thing as FDA law.
After FDA took the position in 2022 that NMN was excluded from the dietary-supplement definition, Amazon removed many NMN supplement listings from its U.S. marketplace.
Questions about:
- whether NMN is currently available on Amazon;
- which sellers list NMN;
- why Amazon removed it;
- how to evaluate marketplace sellers;
belong to our dedicated NMN and Amazon guide.
Does Amazon Selling NMN Mean FDA Approved It?
No.
A retailer choosing to list a supplement does not constitute FDA approval.
Likewise, a retailer choosing not to sell an ingredient does not by itself mean FDA has declared the ingredient toxic or unlawful.
Retailer policy and federal regulatory status are different questions.
Why Was NMN “Off the Market”?
NMN never disappeared universally from every U.S. sales channel.
What changed after the 2022 FDA position was:
- major retailers removed or restricted listings;
- some brands stopped or altered U.S. sales;
- regulatory uncertainty increased;
- the industry challenged FDA's interpretation.
So “off the market” is better understood as substantial marketplace disruption than as a nationwide physical removal of every NMN product.
Was NMN Removed Because It Was Being Studied as a Drug?
The 2022 FDA position centered on the drug-preclusion clause and NMN having been authorized for investigation as a new drug.
However, the later question became:
Was NMN already marketed as a supplement or food before that drug-investigation authorization?
FDA ultimately concluded in 2025 that the answer was yes for purposes of section 201(ff)(3)(B).
That earlier marketing changed the legal analysis.
Does NMN Being Studied as a Drug Make Supplements Illegal?
Not automatically.
The statute includes an exception where the article had already been marketed as a dietary supplement or food before the relevant drug-approval or drug-investigation event.
This “which came first?” question is why the NMN timeline became so important.
Is NMN Approved for Anti-Aging?
No.
No FDA-approved indication exists for NMN to:
- reverse aging;
- extend lifespan;
- prevent age-related disease;
- treat fatigue;
- improve cognition;
- treat metabolic disease.
Human NMN research has demonstrated biochemical activity—particularly increases in NAD+-related biomarkers—but clinical effectiveness varies by outcome.
For the human evidence, see NMN benefits and how it works.
Does FDA Consider NMN Safe?
FDA's decision that NMN is not excluded under the drug-preclusion clause should not be interpreted as a blanket safety endorsement.
Those are separate legal questions.
Human studies provide short-term safety data for several oral NMN amounts, but:
- long-term multi-year safety remains less certain;
- pregnancy safety is not established;
- active cancer-treatment questions require caution;
- finished-product quality can vary.
See our NMN safety and side-effects guide for the clinical evidence.
Are All NMN Supplements Now Legal?
No regulatory change makes every product automatically compliant.
A finished supplement can still violate U.S. law because of issues involving:
- ingredient status;
- manufacturing;
- contamination;
- label accuracy;
- New Dietary Ingredient requirements;
- disease claims;
- adulteration;
- misbranding.
The regulatory status of NMN as an ingredient does not certify every bottle sold online.
Is NMN Just Vitamin B3?
NMN is related to vitamin B3 metabolism, but it should not be treated as interchangeable with niacin or nicotinamide.
NMN is a nucleotide intermediate used in NAD+ biosynthesis.
Nicotinic acid and nicotinamide are established forms of niacin used to meet vitamin B3 nutritional requirements.
NMN supplements are not simply equivalent to ordinary vitamin B3 supplements in identity, dose, regulatory history, or clinical research.
Is NMN Banned in Europe?
The European Union uses a different regulatory system from the United States.
In 2022, European authorities classified nicotinamide mononucleotide as a novel food because a history of significant food consumption in the EU before May 15, 1997 had not been established.5
A novel food generally requires authorization before it can be legally placed on the EU market for the proposed use.
In 2026, the European Food Safety Authority issued a positive safety assessment for a specific β-NMN novel-food dossier, and in September 2026 an EU committee issued a positive opinion on a draft implementing act authorizing β-NMN as a novel food.6
As of this article's review date, that regulatory process should not be described simply as:
- “NMN is banned in Europe”; or
- “all NMN is fully approved across Europe.”
EU novel-food authorization is ingredient- and application-specific and follows a different legal framework from FDA dietary-supplement regulation.
NMN Regulatory Timeline
| Date | Event |
|---|---|
| Before 2022 | Multiple firms submitted New Dietary Ingredient notifications involving NMN. |
| October-November 2022 | FDA concluded NMN was excluded from the dietary-supplement definition under the drug-preclusion clause. |
| March 2023 | Industry groups petitioned FDA to reconsider its interpretation. |
| 2023-2025 | The regulatory dispute continued through petitions and litigation. |
| September 29, 2025 | FDA stated that it no longer finds NMN excluded under section 201(ff)(3)(B), concluding prior U.S. supplement marketing preceded drug-investigation authorization. |
| November 17, 2025 | Effepharm submitted NDI notification 1444 for β-NMN/NMN. |
| January 28, 2026 | FDA's current NDI list records a response to notification 1444. |
Frequently Asked Questions
Why is NMN banned by FDA?
That wording is outdated. FDA concluded in 2022 that NMN was excluded from the dietary-supplement definition under the drug-preclusion clause. In September 2025, FDA reversed that position and said it no longer finds NMN excluded under section 201(ff)(3)(B).
Is NMN banned in the USA?
Not under the FDA drug-preclusion interpretation that drove the 2022 controversy. FDA now says NMN is not excluded from the dietary-supplement definition under that provision.
Is NMN legal in the USA?
FDA no longer treats NMN as excluded under the relevant drug-preclusion clause. Specific finished products still must comply with all other applicable supplement requirements.
Is NMN FDA-approved?
No. Dietary supplements are not FDA-approved for safety and effectiveness before marketing.
Did FDA remove NMN?
FDA did not physically remove all NMN from the market. Its 2022 legal interpretation caused major marketplace disruption and retailer delistings. The agency changed that interpretation in 2025.
Why was NMN taken off the market?
Some retailers and brands changed availability after FDA's 2022 determination that NMN was excluded from the dietary-supplement definition. NMN did not disappear from every U.S. sales channel.
Why did Amazon stop selling NMN?
Amazon removed NMN listings after the 2022 FDA regulatory decision. Amazon marketplace policy is separate from FDA approval or legal classification. See our dedicated NMN and Amazon article for current marketplace details.
What is the controversy with NMN?
The central controversy involved whether NMN's drug-investigation history legally excluded it from the dietary-supplement category, and whether prior supplement marketing occurred early enough to preserve supplement status.
What is NDI 1444?
NDI 1444 is a New Dietary Ingredient notification for β-NMN/NMN submitted by Effepharm in November 2025. FDA's public database lists a response dated January 28, 2026.
Does NDI 1444 mean NMN is FDA-approved?
No. An NDI notification is not FDA approval of a dietary supplement, an anti-aging indication, or a finished product.
Are dietary supplements regulated by FDA?
Yes. FDA regulates dietary supplements, but generally does not approve them for safety and effectiveness before marketing. Manufacturers and distributors are responsible for compliance, while FDA has oversight and enforcement authority.
Why aren't vitamins and supplements FDA-approved?
Congress created a different legal framework for dietary supplements than for drugs. Under DSHEA, most dietary supplements do not undergo premarket safety-and-effectiveness approval.
Does FDA approval prove NMN is safe?
There is no general FDA approval of NMN supplements. Safety should be evaluated from human studies, product quality, dose, health status, medications, and the specific finished product.
Is NMN banned in Europe?
The EU treats NMN as a novel food requiring authorization. In 2026 a specific β-NMN dossier received a positive safety assessment and a draft authorization received a positive committee opinion. This is a different system from U.S. FDA supplement regulation.
The Bottom Line
The statement “FDA banned NMN” describes an important part of the 2022 history, but it is no longer an accurate summary of FDA's current position.
The current record supports these conclusions:
- FDA concluded in 2022 that NMN was excluded from the dietary-supplement definition under the drug-preclusion clause;
- the dispute was primarily about regulatory classification, not a finding that NMN was toxic;
- FDA reconsidered that interpretation in 2025;
- FDA now says NMN is not excluded under section 201(ff)(3)(B);
- FDA's current NDI database includes a β-NMN notification submitted in November 2025 with a response dated January 28, 2026;
- NMN dietary supplements are not “FDA-approved” for safety, effectiveness, anti-aging, or lifespan extension;
- ingredient status does not make every finished NMN product automatically compliant;
- Amazon marketplace availability is a separate issue from FDA legal status.
For current marketplace availability, see why Amazon stopped selling NMN. For safety, see NMN side effects. For the latest study and regulatory updates, see NMN research and news.
References
- U.S. Food and Drug Administration. Supplemental response concerning NDI 1259: β-Nicotinamide Mononucleotide (NMN). November 2022. FDA concluded at that time that NMN was excluded from the dietary-supplement definition under section 201(ff)(3)(B)(ii).
- U.S. Food and Drug Administration. Response to Citizen Petition FDA-2023-P-0872. September 29, 2025. FDA stated that it no longer finds NMN excluded under section 201(ff)(3)(B) and concluded that NMN's first U.S. supplement marketing preceded authorization for investigation as a new drug.
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements. FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.
- U.S. Food and Drug Administration. Submitted 75-Day Premarket Notifications for New Dietary Ingredients. NDI 1444: beta-nicotinamide mononucleotide (β-NMN) or NMN; Effepharm, Ltd.; submitted November 17, 2025; FDA response January 28, 2026.
- European Commission. Consultation request for the determination of the novel-food status of nicotinamide mononucleotide. October 11, 2022. NMN was classified as a novel food under Regulation (EU) 2015/2283.
- European Food Safety Authority and European Commission. β-Nicotinamide Mononucleotide novel-food assessment and 2026 draft implementing act. EFSA issued a positive safety assessment in 2026; the relevant EU committee issued a positive opinion on the draft authorization on September 24, 2026.









